Table 2 Regression coefficients of the mean changes in visual acuity by study group
Follow-up (months) | Change in VA (LogMAR) | ||||||
|---|---|---|---|---|---|---|---|
No Treatmenta | PDT (p-value) | Bevacizumab (p-value) | Ranibizumab (p-value) | ||||
2–4 | 0.27 | 0.18 | (0.2) | −0.01 | (< 0.0001) | −0.12 | (< 0.0001) |
6–8 | 0.38 | 0.34 | (0.6) | 0.002 | (< 0.0001) | −0.10 | (< 0.0001) |
10–12 | 0.54 | 0.48 | (0.5) | 0.09 | (< 0.0001) | 0.07 | (< 0.0001) |
22–24 | 0.69 | 0.61 | (0.5) | 0.12 | (< 0.0001) | 0.13 | (< 0.0001) |